Health & Environmental Research Online (HERO)


Print Feedback Export to File
724950 
Journal Article 
Review 
The toxicology of perfluorooctanoate 
Kennedy, GL; Jr; Butenhoff, JL; Olsen, GW; Connor, JCO; Seacat, AM; Perkins, RG; Biegel, LB; Murphy, , SR; Farrar, DG 
2004 
Yes 
Critical Reviews in Toxicology
ISSN: 1040-8444
EISSN: 1547-6898 
Taylor & Francis Group Ltd., 2 Park Square Oxford OX14 4RN UK 
34 
351-384 
English 
PFOA is a peroxisome proliferator (PPAR agonist) and exerts morphological and biochemical effects characteristic of PPAR agonists. These effects include increased beta-oxidation of fatty acids, increases in several cytochrome P-450 (CYP450)-mediated reactions, and inhibition of the secretion of very low-density lipoproteins and cholesterol from the liver. These effects on lipid metabolism and transport result in a reduction of cholesterol and triglycerides in serum and an accumulation of lipids in the liver. The triad of tumors observed (liver, Leydig cell, and pancreatic acinar-cell) is typical of many PPAR agonists and is believed to involve nongenotoxic mechanisms. The hepatocellular tumors observed in rats are likely to have been the result of the activation of the peroxisome proliferator activated receptor alpha (PPARalpha). The tumors observed in the testis (Leydig-cell) have been hypothesized to be associated with an increased level of serum estradiol in concert with testicular growth factors. The mechanism responsible for the acinar-cell tumors of the pancreas in rats remains the subject of active investigation. The mechanism resulting in the hepatocellular tumors in rats (PPARalpha activation) is not likely to be relevant to humans. Similarly, the proposed mechanism for Leydig-cell tumor formation is of questionable relevance to humans. Acinar tumors of the pancreas are rare in humans, and the relevance of the these tumors, as found in rats, to humans is uncertain. Epidemiological investigations and medical surveillance of occupationally exposed workers have not found consistent associations between PFOA exposure and adverse health effects 
Acids 
IRIS
• Trichloroethylene (TCE) (Final, 2011)
PFAS
• Additional PFAS (formerly XAgency)
     Literature Search November 2019
          Other Sources
               ATSDR
               Reference list review of included studies
     Screened Studies
          Excluded
               Exclude (TIAB)
• Expanded PFAS SEM (formerly PFAS 430)
     Litsearch: September 2019
          PubMed
     Not prioritized for screening
     Potassium perfluorooctanoate
     Sodium perfluorooctanoate
• PFAS 150
     Literature Search August 2019
          PubMed
          Web of Science
          Other sources
               ATSDR
     Screened Studies
          Excluded
               Exclude (TIAB)
     Ammonium perfluorooctanoate
     Perfluorooctanoic acid
• PFHxS
     Background References
• PFOA and PFOS OW MCLG Approaches
     Cited in White Papers
• R5-MI STSC Request